Clinical trial · Observational
Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients
Vedio-assisted Thoracoscopic Lobectomy vs Open Lobectomy for Patients With Surgically Resectable Pathologic N2 NSCLC
NCT03613467CI-TRIAL-00034228completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thoracotomy lobectomy | Procedure | — | UNRESOLVED |
| VATS lobectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- VATS lobectomy
- description
- Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
- interventionNames
- Procedure: VATS lobectomy
- label
- Thoracotomy lobectomy
- description
- Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
- interventionNames
- Procedure: Thoracotomy lobectomy
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2014-2018
- description
- Overall survival
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with age \> 18 years old; * Patients with pathologically diagnosed non-small cell lung cancer; * Patients underwent lobectomy by either VATS or thoracotomy between 2014 and 2017; * Patients who received lymphadenectomy for all accessible lymph nodes; * Patients with N2 lymph nodes (+) after surgeries; Exclusion Criteria: * Patients with second primary tumors or multiple primary tumors; * Patients who received chest surgeries before hospitalization; * Patients with superior pulmonary sulcus tumor
References
Publications (0)
Data not yet available
No reference posted for this study.